In children and adolescents with episodic migraine, fremanezumab led to a greater reduction in migraine days per month than placebo (−2.5 days vs. −1.4), and nearly half of recipients had a reduction of 50% or more in migraine days.
Emergency Medicine
|11th Mar, 2026
|The New England Journal of Medicine
Emergency Medicine
|11th Mar, 2026
|The New England Journal of Medicine
Emergency Medicine
|11th Mar, 2026
|The New England Journal of Medicine
Emergency Medicine
|11th Mar, 2026
|The New England Journal of Medicine
Emergency Medicine
|11th Mar, 2026
|The New England Journal of Medicine
Emergency Medicine
|11th Mar, 2026
|The New England Journal of Medicine
Emergency Medicine
|11th Mar, 2026
|The New England Journal of Medicine